SBIR/STTR Research Award
Hemostatic Agent Development
Award amount
$70,000Program and phase
SBIR · Phase IAward year
2010Award details
- Awarding agency
- Department of Defense
- Branch
- Navy
- Recipient company
- HYBRID PLASTICS
- Proposal award date
- 2010-09-21
- Contract end date
- 2011-07-26
- UEI
- MPMJGN56FGB5
- Solicitation number
- 2010.1
- Topic code
- N101-085
Research abstract
The proposed effort comprises a treatment combination using the platelet binding hemostatic capability of Nanoscopic Chemicals known as POSS trisilanols in combination with hyaluronic acid media, and antibiotic drugs in liquid and foam form. Mechanistically, liquid POSS trisilanols are injectable and serve to bind platelets to immediately stop bleeding. Subsequently the bound plateles release a multitude of natural growth factors while in the presence of a supplement of Hyaluronic acid (HA). Growth factors in combination with high amounts of HA are known to aid tissue repair and preservation.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Hemostatic Agent Development
- POSS Nanochemical Technology for Radiation Hardened/Tolerant Systems
- Solid Polymer Electrolytes with High Lithium Ion Conductivity and Transport Number for Hybrid Electric Power-train Systems
- Anion Exchange Polymer Membranes Based on Polyoctahedral Silsesquioxanes for Alkaline Fuel Cells
- POSS TCP Resin System for Carbon Fiber Reinforced Composite Shipboard Applications
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
21 SBIR/STTR records share this UEI (2001–2020). Reported award amounts total $6,722,188. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Defense, National Science Foundation, Department of Health and Human Services, Department of Energy